文献速递淋巴瘤

真实世界848例慢性淋巴细胞白血病淋巴细胞倍增时间的现代意义

Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.
PubMed 文献 · Leukemia · 2021-02-04

该研究在848例未选择慢性淋巴细胞白血病患者中评估淋巴细胞倍增时间(LDT)的临床与生物学意义。短LDT(≤12个月)富集不良生物标志物,患者更早需要治疗且总生存更差。LDT独立于CLL-IPI和Barcelona/Brno模型预测结局,仍具重要价值。

要点

  • 短LDT(≤12个月)与不良生物标志物富集相关。
  • 短LDT患者更早需治疗(中位23个月 vs 未达到)且总生存更差(中位95个月 vs 未达到)。
  • LDT独立于CLL-IPI和Barcelona/Brno模型预测生存,应纳入临床评估。

核心结论

  • LDT在现代CLL时代仍是重要结局标志物,应纳入临床评估与分层。

研究设计与样本

  • 真实世界研究,纳入848例未选择的慢性淋巴细胞白血病患者。

主要发现

  • 短LDT(≤12个月)富集不良生物标志物。
  • 短LDT患者更早需治疗(中位23个月 vs 未达到;p<0.001)。
  • 短LDT患者总生存更差(中位95个月 vs 未达到;p<0.001)。
  • LDT、IGHV突变状态、Beta-2微球蛋白和Rai临床分期是全系列及Binet A期患者至首次治疗时间的独立预测因素。
  • LDT与化学免疫治疗反应无相关性。

关键数值与推荐

  • 短LDT(≤12个月)联合年龄≥65岁、高危FISH(del(17p)、del(11q))、未突变IGHV、Beta-2微球蛋白升高和TP53突变预测短生存。
  • LDT的预后意义独立于CLL-IPI和Barcelona/Brno预后模型。

临床怎么用

  • 临床评估CLL患者时应计算LDT,尤其短LDT提示早期治疗需求和不良生存。
  • LDT可结合IGHV、Beta-2微球蛋白、Rai分期等用于至首次治疗时间的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic significance of lymphocyte doubling time (LDT) in chronic lymphocytic leukemia (CLL) was identified when the biology of the disease was poorly understood and therapy was not effective. We assessed the clinical and biological significance of LDT in 848 CLL patients in a real-life setting and the context of new biomarkers and effective therapy. A short LDT (≤12 months) was enriched for adverse biomarkers. Patients with a rapid LDT did need therapy shortly after diagnosis (median 23 months vs. not reached; p < 0.001) and had a poorer overall survival (median 95 months vs. not reached p < 0.001). LDT, IGHV mutational status, Beta-2 microglobulin, and Rai clinical stage were independent predictors for time to first treatment in the whole series and in Binet stage A patients. No correlation was observed between LDT and response to chemoimmunotherapy. However, a short LDT along with age ≥65 years, high-risk FISH (del(17p), del(11q)), unmutated IGHV, increased Beta-2 microglobulin, and TP53 mutations predicted short survival. Moreover, the prognostic significance of LDT was independent of the CLL-IPI and the Barcelona/Brno prognostic model. LDT remains an important outcome marker in the modern CLL era and should be incorporated into the clinical assessment and stratification of CLL patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Baumann T, Moia R, Gaidano G, et al. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. Leukemia. 2021. PMID: 33542480. doi:10.1038/s41375-021-01149-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。